These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 18063611)

  • 1. Effect of European Clinical Trials Directive on academic drug trials in Denmark: retrospective study of applications to the Danish Medicines Agency 1993-2006.
    Berendt L; Håkansson C; Bach KF; Dalhoff K; Andreasen PB; Petersen LG; Andersen E; Poulsen HE
    BMJ; 2008 Jan; 336(7634):33-5. PubMed ID: 18063611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methodological characteristics of academic clinical drug trials--a retrospective cohort study of applications to the Danish Medicines Agency 1993-2005.
    Berendt L; Håkansson C; Bach KF; Andreasen PB; Petersen LG; Andersen E; Poulsen HE; Dalhoff K
    Br J Clin Pharmacol; 2010 Nov; 70(5):729-35. PubMed ID: 21039767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The role of the Danish Medical Products Agency in clinical trials].
    Simonsen AC
    Ugeskr Laeger; 2003 Apr; 165(16):1653-6. PubMed ID: 12756821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Good clinical practice is now obligatory in academic clinical drug research in the European Union.
    Jørgensen A; Bach KF; Friis K
    Basic Clin Pharmacol Toxicol; 2004 Feb; 94(2):57-8. PubMed ID: 14748847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of the European Clinical Trials Directive on published drug research in anaesthesia.
    Walker E; Hankins MC; White SM
    Anaesthesia; 2009 Sep; 64(9):984-9. PubMed ID: 19686484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Barriers towards the publication of academic drug trials. Follow-up of trials approved by the Danish Medicines Agency.
    Berendt L; Petersen LG; Bach KF; Poulsen HE; Dalhoff K
    PLoS One; 2017; 12(5):e0172581. PubMed ID: 28486523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishing pan-European clinical trials: regulatory compliance and other practical considerations.
    Grienenberger A
    J Biolaw Bus; 2004; 7(4):58-63. PubMed ID: 15675097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The 12th amendment to the German Drug Law. Chances and obstacles for investigator-initiated clinical trials].
    Dreier G; Marx C; Schmoor C; Maier-Lenz H
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):445-52. PubMed ID: 15830256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the European Clinical Trials Directive on academic clinical research.
    Baeyens AJ
    Med Law; 2004; 23(1):103-10. PubMed ID: 15163079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The inspection by the Danish Medical Products Agency of drug clinical trials].
    Jacobsen E; Stilbo I
    Ugeskr Laeger; 2003 Apr; 165(16):1656-8. PubMed ID: 12756822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of the GCP Directive on academic drug trials].
    Berendt L; Håkansson C; Bach KF; Dalhoff K; Andreasen PB; Petersen LG; Andersen E; Poulsen HE
    Ugeskr Laeger; 2008 Aug; 170(33):2437-9. PubMed ID: 18761825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. European Commission considers revisions to clinical trials directive.
    Mason E
    J Natl Cancer Inst; 2010 Mar; 102(5):292-4, 297. PubMed ID: 20173121
    [No Abstract]   [Full Text] [Related]  

  • 13. [The GCP directive--consequences for clinical drug research].
    Gluud CN
    Ugeskr Laeger; 2003 Apr; 165(16):1662-4. PubMed ID: 12756824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Reporting adverse reactions and events in randomised clinical trials].
    Hemmingsen B; Støy L; Wetterslev J; Tarnow L; Friis KB; Christensen LL; Sales N; Gluud C;
    Ugeskr Laeger; 2010 Aug; 172(35):2381-4. PubMed ID: 20825743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory Capture in Pharmaceutical Policy Making: The Case of National Medicine Agencies Related to the EU Falsified Medicines Directive.
    Borup R; Traulsen JM; Kaae S
    Pharmaceut Med; 2019 Jun; 33(3):199-207. PubMed ID: 31933284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Academic clinical research in the new regulatory environment.
    Gennery B
    Clin Med (Lond); 2005; 5(1):39-41. PubMed ID: 15745196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The death of academic clinical trials.
    Morice AH
    Lancet; 2003 May; 361(9368):1568. PubMed ID: 12737908
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [How to establish GCP-units in Denmark?].
    Krogsgaard K; Andreasen PB
    Ugeskr Laeger; 2003 Apr; 165(16):1665-7. PubMed ID: 12756825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.